Google Ad

Lupin will get tentative nod from USFDA to market kind 2 diabetes drug – Home Health Choices

New Delhi: Drug agency Lupin on Thursday mentioned it has acquired tentative nod from the US well being regulator to market generic Empagliflozin and Linagliptin tablets, used as an adjunct to food regimen and exercise to enhance glycemic management in adults with kind 2 diabetes. The product is a generic model of Boehringer Ingelheim Pharmaceuticals Inc’s Glyxambi tablets in the identical strengths, Lupin mentioned in a press release.

The firm has acquired tentative approval to market Empagliflozin and Linagliptin tablets within the strengths of 10 mg/5 mg and 25 mg/5 mg, from the United States Food and Drug Administration (USFDA), it added.

According to IQVIA MAT March 2020 knowledge, Empagliflozin and Linagliptin tablets, 10 mg/5 mg and 25 mg/5 mg had an annual gross sales of roughly USD 242 million within the US.

The tablets are indicated as an adjunct to food regimen and exercise to enhance glycemic management in adults with kind 2 diabetes mellitus, it knowledgeable.

Shares of Lupin Ltd closed at Rs 862.85 per scrip on the BSE, up 1.37 per cent from its earlier shut.

Latest Updates

Related Post